There are not effective therapies for metastatic unresectable, non-radioactive iodine (RAI)-avid thyroid carcinomas. Fortunately, thyroid carcinomas represent a promising paradigm for targeted therapy due to the presence of activating mutations of genes coding the kinase tyrosines that are involved in all functions of cancer cells (such as growth or invasion). In this paper, an efficacy and toxicity of sorafenib, one of the multi-kinase inhibitors in thyroid carcinomas treatment, is presented.
and VEGFR 3), platelet-derived growth factor receptor beta (PDGFR), c-KIT, Flt-3. [2] [3] [4] In addition, sorafenib inhibits wild-type and mutant BRAF V600E. 4 Overexpression of VEGFR and other growth factors is commonly found in tumours of thyroid origin particularly those having BRAF mutations. 5 These findings provided the rationale for using sorafenib in patients with metastatic, non-radioactive iodine (RAI)-avid thyroid cancer. 5 The drug may potentially inhibit thyroid cancer growth both through anti-proliferative and anti-angiogenic mechanisms. [2] [3] [4] Sorafenib is approved as treatment for metastatic clear cell renal carcinoma and advanced, unresectable hepatocellular carcinoma. 6 Sorafenib is given orally at a dose of 400 mg twice daily until disease progression or unacceptable toxicity.
Results of current trials with sorafenib in patients with thyroid carcinomas present Table 1 .
Differentiated Thyroid Carcinoma
Although the prognosis for differentiated thyroid cancer is good, about 5 % to 20 % of patients develop distant metastases about half of which does not respond to conventional therapy such as radioactive iodine (RAI). 4, 7, 8 Conventional chemotherapy response rate is assessed as a maximum 25 % and chemotherapy causes marked toxicity. For those diagnosed under 45 years with distant metastases survival steadily declines. Long-term survival for patients with stage IV is about 43 % and about 86 % for those with stage I of disease. 4 In case of RAI-resistant disease overall survival drops to 10 %.
All histological subtypes have similar responses for sorafenib therapy. 4, 9, 10 Radiological response is not influenced by gender, age or the presence of BRAF V600E mutation. 10 According to other authors the effect of sorafenib seems to be more potent in patients with papillary thyroid carcinoma than follicular or poorly differentiated carcinoma and with BRAF mutation than with wild-type BRAF. 9, 11 The response occurs in the lung, but not in the non-irradiated bone and pleural metastases. Lymph nodes respond but less robustly. 4, 10, 11 Patients with bone metastases had significantly worse median progression-free survival and median overall survival than patients without metastases to bones. 10, 12 It suggests a tissue-specific response to therapy. These differences in response seem to be either the result of differential expressions and different inhibitions of various VEGF receptors or due to a non-VEGFR-mediated mechanism, such as differences in drug level in tissues. 4 In a trial by Ahmed et al. partial response after sorafenib treatment in the patients with lung or liver metastases, but not in patients with thyroid and retrosternal masses, was observed. The authors suggested that sorafenib might be more effective against small volume tumours, the tumour vascularity is the major factor in determining response.
Sorafenib appears to be a useful agent in patients with advanced, progressive differentiated thyroid carcinoma and demonstrates welltolerated toxicity profile. 13, 14 Prolonged disease stabilisation is more commonly seen than partial response. On the basis of papillary thyroid carcinoma cells line carrying the RET/ PCT1 rearrangement and BRAF mutation revealed that papillary thyroid carcinoma cells carrying the RET/PCT1 rearrangement were more sensitive to sorafenib than the cell-carrying BRAF mutation. 17 However greater efficacy was observed in papillary carcinoma especially with BRAF mutation than in poorly differentiated thyroid carcinoma. Sorafenib had no effect on iodine uptake. 20 These findings can be helpful to identify patients who most likely respond to sorafenib therapy.
In a Phase II trial, clinical benefit (based on partial remission and stable disease) was six months and more in 56 % of papillary thyroid carcinoma patients. Median duration of partial remission was 7.5 months and median progression-free survival was 15 months. 16 In a Chinese study, which enrolled nine patients with radioiodinerefractory pulmonary metastases of papillary thyroid carcinoma, a daily dose of sorafenib was smaller (200 mg twice daily) than the standard dose (400 mg twice daily according to drug characteristics) was administered. The results confirmed the efficacy of smaller doses of sorafenib. The objective partial response rate was 33 %,the stable disease rate was 44 % and the mean progression free survival was 42 weeks. 21 Paediatric papillary thyroid carcinoma typically presents with more advanced disease compared with adults, but the prognosis even in the presence of distant metastatic disease is excellent.
One case with progressive RAI-refractory lung metastases from papillary thyroid carcinoma treated with sorafenib has been described in the medical literature so far. After two months of therapy the response was very good. Unfortunately, there are limited data to recommend sorafenib in this kind of tumour. 27 RET mutations have not proven so far whether patients will respond to multikinase inhibitors. 27 For medullary thyroid carcinomas, almost all familiar forms of the disease arise due to inheritable germline-activating mutations in RET, and identical somatic mutations occurring in C cells commonly causing sporadic disease. 6, 19 Preclinical findings suggested that sorafenib might offer a potential treatment strategy for medullary thyroid carcinoma, thus enabling oncogenic activation of RET. 19 In a small study, five patients with metastatic medullary thyroid carcinoma were treated with sorafenib: one complete remission and one partial remission were described and symptomatic improvement was observed in all patients. 28 Although only one partial remission was observed in patients with sporadic medullary thyroid carcinoma, 50 % of patients demonstrated stable disease lasting six months or longer, with tumour shrinkage ranging from 8 to 27 % on the basis of Phase II trial. 26 The median progression-free survival was 17.9 months and the median overall survival time was not reached at the time of analysis. 2 According to data from a Phase II UK study in medullary thyroid carcinoma patients the radiological response rate was 25 % and the overall survival -100 % after 12 months.
The progression-free survival rate of two years in these patients was 84% and the overall survival rate was 90 %. with radiotherapy was found to be safe. 32 In a Phase II study, Savvides et al. assessed the efficacy and toxicity of sorafenib in 16 pretreated patients with anaplastic thyroid carcinoma.
The disease-control rate (stable disease and partial response) was 40 % and toxicity was manageable. 35 In a Spanish trial, the response rate was 33 % (one out of three patients with anaplastic thyroid carcinoma who were enrolled). The median progression-free survival was 4.4 months. 15 Sorafenib demonstrates an acceptable response rate in anaplastic thyroid carcinoma and further clinical trials are warranted, but due to the rarity of this tumour such a trial will be hard to accomplish.
Toxicity
The side effects of sorafenib differ from the typical anticancer (cytotoxic) drugs. Appetite loss/weight loss, fatigue, hypertension, skin lesions, diarrhoea, hypocalcaemia, hypothyroidism, mucositis and musculoskeletal pain are the most common toxicities. [2] [3] [4] 6, 9, 10, 20, 24, 26, 36 Hand-foot reaction and maculo-papular skin rash are the most common dermatological adverse events. 2, 4 In some cases (like other agents inhibit BRAF) sorafenib has been also associated with development of cutaneous squamous cell carcinomas in up to 5 % of treated patients and a similar frequency of keratoacanthomas and other premalignant actinic lesions. 4, 16, 37 In general, the side effects are mostly mild. 7, 26, 36 Haematological abnormalities including neutropoenia, lymphopenia, thrombocytopenia are more common than anaemia during sorafenib therapy. Grade 3 and 4 haematological toxicities seldom occur in thyroid cancer patients receiving sorafenib. 36 There are described single cases of a myocardial infarction and systolic and diastolic congestive heart failure. 10, 12, 36 Rare adverse events such as bleeding and liver toxicity can be fatal. 35 In the first study reporting long-term effects of sorafenib, the majority of adverse events were seen in the first year of treatment. These side effects were well-tolerated. 12 Furthermore, treatment of all comorbid conditions (e.g. hypertension)
should be optimised and regular thyroid-stimulating hormone (TSH)
tests are necessary because of increasing TSH level during sorafenib therapy. Oral thyroid hormonal therapy is administered as needed.
20,36
Further Investigations Tolerance of treatment was good. 40 In another study, combination therapy sorafenib and withaferin A (a natural withanolide) showed preclinical anticancer activity against anaplastic and papillary thyroid carcinoma through both anaplastic induction and cell-cycle arrest. There are more and more published clinical cases confirming high activity of sorafenib in thyroid carcinomas. 43, 44 We treated three patients with metastatic differentiated thyroid carcinoma with very satisfactory results. Among those patients, we observed a case of 58-year-old male with metastatic lesions to the lungs with 26-month partial response to sorafenib. According to our experience, the treatment toxicity of sorafenib in our group of the patients was moderate and easily manageable. ■
